Archived Faculty News
Sanchez de Lozada has little sympathy in Bolivia today - even leading opposition party politicians have stated publicly that he should be brought to trial. A bad reputation, however, notes Jules Lobel, Professor at University of Pittsburgh School of Law and Vice President of the Center for Constitutional Rights, isn't a legal defense. "While the United States may claim that the accusations fall under the rubric of the political offense exception," says Lobel, "in my opinion the massacre of hundreds of civilians should not be considered a political offense."Link: http://www.time.com/time/world/article/0,8599,1586707,00.html
Professor Janice Mueller, Director of Pitt Law's Certificate Program in Intellectual Property and Technology Law, has published "Taking TRIPS to India--Novartis, Patent Law, and Access to Medicines" as a Perspective in the New England Journal of Medicine. Regarding Novartis's efforts to obtain Indian patent protection for a leukemia treatment, she writes:
India has an independent judiciary and an established rule-of-law tradition. Novartis's litigation needs to run its course, and the system must be allowed to do its job, since a number of important results could flow from this case. Indian courts probably cannot use the WTO's rules to strike down laws enacted by India's parliament, but the Chennai High Court will have to grapple with the meaning of Section 3(d) and other untested patent rules. Regardless of the outcome, the system will benefit from the judicial analysis. And even if Novartis ultimately obtains an Indian patent on Gleevec, the current safeguards give the government multiple options for ensuring public access to this and other lifesaving drugs.Link: http://content.nejm.org/cgi/content/full/356/6/541 An audio interview with Professor Mueller is also posted at the site, at http://content.nejm.org/cgi/content/full/356/6/541/DC1 UPDATED 2/20: Ongoing coverage and reprints of Professor Mueller's NEJM article: Pharma Week: http://www.pharmaweek.com/Business_and_Markets/Novartis%20Fight.asp European AIDS Treatment Group: http://www.eatg.org/news/newsitem.php?id=899 The Commonwealth Secretariat: http://www.thecommonwealth.org/news/159818/taking_trips_to_india___novartis__patent_law__and.htm ZENCast: http://www.zencast.com/channels/showchannel.asp?mc=3&cid=1864 DrugWorks.com, from the Center for Medicine in the Public Interest: http://www.drugwonks.com/2007/02/not_all_patents_created_equal.html
The old saying, "Who watches the watchman?" is as true as it ever was. Very old, frail and demented elderly need a watchman, but they also need someone who is keeping an eye on the watchman. An essential aspect of planning for agents and surrogates is to provide oversight lest the watchman become the exploiter. As in so many aspects of life, a little planning can prevent a great deal of pain.Link: http://www.wealthstrategiesjournal.com/Issue_2007_01/2007_01_COL_02_p02.html


